Astena Holdings Co.,Ltd. Q3 FY2025 earnings call

• Overall Third Quarter Financial Performance

  • The company achieved 45.47 billion yen in total revenue (8.1% increase year-over-year), 2.8 billion yen in operating profit (40.1% increase year-over-year), 2.71 billion yen in ordinary profit (34.7% increase year-over-year), 1.63 billion yen in net profit attributable to parent company shareholders (43.7% increase year-over-year), and 4.56 billion yen in EBITDA (23.2% increase year-over-year), delivering both revenue and profit growth.
  • Growth was primarily driven by strong performance of development consignment in Fine Chemical Business and imported cosmetic sales in HBC & Food Business.
  • Strategic & Operational Updates
  • Introduced a "Special Incentive Scheme" through the employee stock ownership association, which grants company shares to members to foster employees' awareness of management participation, strengthen group unity, and motivate efforts to increase corporate value.
  • Fine Chemical Business: The pharmaceutical development ecosystem division focused on acquiring new projects, with growing new orders led by MicroED-related projects and steady growth in middle-molecule API process development projects. The pharmaceutical raw material platform division saw steady sales of high value-added products via proposal-based sales, though costs increased due to headcount expansion for business growth and office relocation. The pharmaceutical CDMO division raised factory utilization by introducing a 2-shift system for external preparation manufacturing, with rising demand for high-quality APIs amid growing active new drug development.
  • HBC & Food Business: The food raw material division saw growing registered users for i-Platto and expanding sales of high value-added products amid gradual market recovery. The cosmetic raw material division saw underperformance due to rising raw material and labor costs, but increased new customer acquisition after strengthening planning and inside sales functions, with associated costs from aggressive sales expansion and M&A activities. The life science division gained new customers after optimizing sales resources despite market contraction. The cosmetic manufacturing and sales division saw strong sales of Korean cosmetic brand Torriden, with increased upfront investment for the newly launched cosmetic planning and development solution service.
  • Pharmaceutical Business: The pharmaceutical division saw strong sales of generic drugs designated as selected treatment items, but slow sales for some generics whose drug prices became equal to or higher than originator drugs after drug price revision. It also faced continued production suspension for some products due to raw material shortages and increased SG&A from accelerated R&D spending. The aesthetic medical division saw strong sales of medical-exclusive cosmetic lines NAVISION DR and illsera as brand awareness grew.
  • Chemical Business: The surface treatment chemical division saw flat performance with no market recovery, though electronic component chemicals performed steadily from new overseas customer acquisition, with a focus on promoting high value-added products including fine wiring formation chemicals, plating chemicals for passive components, and semiconductor electrode formation chemicals. The surface treatment equipment division saw lower sales after customers completed their capital investment cycles, but non-equipment sales (repairs, maintenance, parts) hit an all-time high due to focused efforts on this segment.
  • Social Impact Business: The healthcare division carried out NAIA brand refresh under the "agriculture x healthcare" concept, with strategic upfront investment for future growth and increased PR investment to raise brand awareness, leading to lower profit. The regional revitalization division saw growing adoption of the local payment service Furusato NOW expanding across Japan, with steady revenue and profit growth that supports regional economic activation and social contribution.
  • Mid-Term Structural Reform
  • Since transitioning to a holding company (HD) structure, the company has steadily advanced structural reform across business segments.

1. Fine Chemical Business: Revenue of 17.17 billion yen, an increase of 1.96 billion yen year-over-year; operating profit of 1.08 billion yen, an increase of 1.21 billion yen year-over-year, contributing 37.8% of total third quarter revenue.
2. HBC & Food Business: Revenue of 12.14 billion yen, an increase of 1.52 billion yen year-over-year; operating profit of 0.54 billion yen, an increase of 0.23 billion yen year-over-year, contributing 26.7% of total third quarter revenue.
3. Pharmaceutical Business: Revenue of 9.31 billion yen, an increase of 0.85 billion yen year-over-year; operating profit of 0.88 billion yen, a decrease of 0.19 billion yen year-over-year, contributing 20.5% of total third quarter revenue.
4. Chemical Business: Revenue of 6.8 billion yen, a decrease of 0.95 billion yen year-over-year; operating profit of 0.41 billion yen, a decrease of 0.33 billion yen year-over-year, contributing 15.0% of total third quarter revenue.
5. Social Impact Business: Revenue of 0.03 billion yen; operating loss of 0.27 billion yen, contributing less than 0.1% of total third quarter revenue.

• Full-year 2025 November Term guidance is maintained at 64.0 billion yen in total revenue (10.4% increase year-over-year), 3.1 billion yen in operating profit (10.1% increase year-over-year), and a 7.0% ROE. Revenue is expected to come in line with the original forecast, while operating profit is projected to exceed the prior year level on the back of strong performance so far.
  • Fine Chemical Business is expected to continue seeing strong performance from high value-added consignment and manufacturing, while HBC & Food Business is expected to remain the growth driver from expanding imported cosmetic sales.
  • The 3-year medium-term management plan ending in the 2027 November Term maintains its target of 70.0 billion yen in total revenue, 3.5 billion yen in operating profit, and an 8.8% ROE.
  • Medium-term strategic priorities include: improving profitability in Fine Chemical Business via sales and consignment system restructuring and efficiency gains; expanding sales channels and pursuing agile M&A in HBC & Food Business; stabilizing profit in niche segments for Pharmaceutical and Chemical Businesses.

• Pharmaceutical Business: Continued production shutdown of some products due to raw material shortages; weak sales of some generic drugs after drug price revision; increased selling, general and administrative costs from accelerated R&D spending.
• Chemical Business: No market recovery for surface treatment chemicals; reduced equipment sales after customers completed their capital investment cycles.
• HBC & Food Business: Cosmetic raw material segment underperformance due to rising raw material and labor costs; upfront investment costs for new service initiatives and M&A activities.
• Fine Chemical Business: Increased expenses from headcount growth and office relocation to support business expansion.
• Social Impact Business: Reduced current profit from large upfront strategic investment for long-term brand building and business expansion.

No substantive question and answer section was included in the provided earnings call transcript.